PRODUCT

Bioglutide

No short description available.

Chain Length:Small cyclic structure
Sequence Type:Cyclic IGF-1 fragment derivative
Molecular Weight:Proprietary (small molecule)
Amino Acid Sequence:Proprietary - derived from cyclic glycine-proline analog of IGF-1
Modification:Lipophilic small molecule optimized for oral bioavailability and BBB penetration

Weight Loss

moderate

Obesity
Phase 2 trial showed 13.8% body weight loss at 150mg daily over 13 weeks. 72% achieved ≥12% weight loss. Advancing to Phase 3 trials.
Muscle Preservation
Unique among weight loss compounds - no muscle loss observed in clinical trials. IGF-1 activation supports anabolic pathways during caloric deficit.
Metabolic Health
Comprehensive metabolic improvement including glucose control, lipid profiles, and liver fat reduction.

Diabetes

effective

Type 2 Diabetes
In active clinical development for T2DM. Multi-receptor approach enhances glucose homeostasis beyond single-agonist therapies.
Insulin Resistance
IGF-1 and GLP-1 receptor activation improves insulin sensitivity. Phase 1 showed glycemic improvements.
Prediabetes
May help reverse metabolic dysfunction and prevent progression to T2DM through comprehensive receptor activation.

Metabolic

effective

NAFLD/Liver Fat
Preclinical studies showed 46% reduction in liver triglyceride content. Potential for fatty liver disease treatment.
Dyslipidemia
34% triglyceride reduction in preclinical models. GIP activation improves lipid handling.
Metabolic Syndrome
Multi-target approach addresses multiple components of metabolic syndrome simultaneously.

Tirzepatide

Being Studied

Active clinical trial (NCT06732245) evaluating NA-931 + Tirzepatide combination for enhanced weight loss

Semaglutide

Avoid Combination

Both activate GLP-1 receptors - combining creates redundancy and compounded GI side effects risk

Retatrutide

Avoid Combination

Both are multi-agonists targeting overlapping pathways (GLP-1, GIP, glucagon) - avoid stacking

CJC-1295

Compatible

Different mechanisms - CJC-1295 stimulates GH release while Bioglutide targets metabolic receptors. May complement for body composition

Ipamorelin

Compatible

May help maintain metabolic rate and support muscle preservation during weight loss

BPC-157

Compatible

No known interactions - BPC-157 may support gut health during GLP-1 therapy

5-Amino-1MQ

Compatible

NNMT inhibition may complement metabolic effects for enhanced fat loss

MOTS-c

Compatible

Different metabolic pathways - may be synergistic for fat loss and energy metabolism

Resources